Answers are grounded in this paper and cite their sources.
Investigates primaquine diphosphate's effects on imatinib-resistant CML, suggesting new treatment options.
Chronic myeloid leukemia (CML) is defined by the Philadelphia chromosome-derived BCR::ABL1 fusion gene. Imatinib, a first-line treatment targeting the BCR-ABL protein, has markedly improved clinical outcomes in patients with BCR::ABL1 + CML. However, drug resistance remains a critical therapeutic challenge in the management of CML. In this study, we uncovered that low concentrations of antimalarial drug primaquine diphosphate (PRQ) induced the differentiation of imatinib-resistant CML cells, while high concentrations triggered their apoptosis. Mechanistically, PRQ inhibited the Wnt/β-catenin pathway and promoted the degradation of both wild-type and multiple imatinib-resistant BCR::ABL1 mutants. Furthermore, PRQ effectively induced differentiation, inhibited colony formation of primary CML blasts, and suppressed the neoplastic growth of imatinib-resistant CML cells in a murine xenograft model. These findings suggest that the antimalarial drug PRQ may have potential for overcoming imatinib resistance in CML, warranting further evaluation as a repurposed candidate.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: